[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100653478":3},{"organization":4,"outcomesModule":7,"designInfo":35,"detailedDescription":38,"studyPopulation":38,"armGroups":42,"interventions":49,"overallOfficials":59,"centralContacts":64,"locations":69,"responsibleParty":94,"collaborators":38,"id":96,"slug":97,"hasResults":98,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":38,"eligibilityCriteria":102,"healthyVolunteers":98,"sex":103,"minAge":104,"maxAge":38,"enrollmentInfo":105,"targetDuration":38,"studyType":108,"phases":109,"briefSummary":111,"conditions":112,"keywords":38,"overallStatus":71,"whyStopped":38,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":124},{"fullName":5,"class":6},"Hefei Cancer Hospital of the Chinese Academy of Sciences","NETWORK",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":30},[9],{"measure":10,"description":11,"timeFrame":12},"Pathological complete response rate","The proportion of patients achieving pathological complete response (absence of viable tumor cells in primary lesion and regional lymph nodes) evaluated by pathological examination of surgical specimens.","At the time of surgical resection.",[14,18,22,26],{"measure":15,"description":16,"timeFrame":17},"Objective Response Rate","The proportion of participants with confirmed complete response (CR) or partial response (PR) assessed per RECIST 1.1.","At the end of Cycle 2, Cycle 4, (each cycle is 21 days).",{"measure":19,"description":20,"timeFrame":21},"Progression-free survival","Time from enrollment to disease progression (per RECIST 1.1) or death from any cause, whichever occurs first.","From date of enrollment until the date of first documented progression or death from any cause, whichever came first, assessed up to 24 months.",{"measure":23,"description":24,"timeFrame":25},"Overall Survival","Follow-up via outpatient visits or telephone interviews; defined as time from enrollment to death from any cause.","From date of enrollment until death from any cause, assessed up to 24 months.",{"measure":27,"description":28,"timeFrame":29},"Duration of Response","Time from first observation of confirmed CR or PR to disease progression or death from any cause, assessed per RECIST Version 1.1.","From the date of first documented confirmed response until disease progression or death from any cause, assessed up to 24 months.",[31],{"measure":32,"description":33,"timeFrame":34},"Adverse events","Adverse events graded by CTCAE Version 5.0; safety follow-up within 90 days after last study drug administration to monitor outcomes of adverse events.","Baseline up to 90 days after last study treatment.",{"allocation":36,"interventionModel":37,"interventionModelDescription":38,"primaryPurpose":39,"observationalModel":38,"timePerspective":38,"maskingInfo":40},"NA","SINGLE_GROUP",null,"TREATMENT",{"masking":41,"maskingDescription":38,"whoMasked":38},"NONE",[43],{"label":44,"type":45,"description":38,"interventionNames":46},"Interferon-γ combined with camrelizumab and neoadjuvant chemotherapy","EXPERIMENTAL",[47,48],"Drug: Interferon-γ","Drug: Camrelizumab",[50,55],{"type":51,"name":52,"description":53,"armGroupLabels":54,"otherNames":38},"DRUG","Interferon-γ","1,000,000 IU administered intravenously on Day 1 of each 3-week cycle for a total of 3-4 cycles.",[44],{"type":51,"name":56,"description":57,"armGroupLabels":58,"otherNames":38},"Camrelizumab","200 mg administered intravenously on Day 1 of each 3-week cycle for a total of 3-4 cycles.",[44],[60],{"name":61,"affiliation":62,"role":63},"Hongzhi Wang","Hefei Cancer Hospital, Chinese Academy of Sciences","STUDY_CHAIR",[65],{"name":61,"role":66,"phone":67,"phoneExt":38,"email":68},"CONTACT","+86 551 6589 5180","wanghz@hfcas.ac.cn",[70,84],{"facility":62,"status":71,"city":72,"state":73,"zip":38,"country":74,"countryCode":75,"cosmosGeoPoint":76,"geoPoint":81,"contacts":82},"RECRUITING","Hefei","Anhui","China","CN",{"type":77,"coordinates":78},"Point",[79,80],117.28083,31.86389,{"lat":80,"lon":79},[83],{"name":61,"role":66,"phone":67,"phoneExt":38,"email":68},{"facility":85,"status":71,"city":72,"state":73,"zip":38,"country":74,"countryCode":75,"cosmosGeoPoint":86,"geoPoint":88,"contacts":89},"The First Affiliated Hospital of Anhui Medical University",{"type":77,"coordinates":87},[79,80],{"lat":80,"lon":79},[90],{"name":91,"role":66,"phone":92,"phoneExt":38,"email":93},"Huaguang Pan","15776762369","68618385@qq.com",{"type":95,"investigatorFullName":38,"investigatorTitle":38,"investigatorAffiliation":38,"oldNameTitle":38,"oldOrganization":38},"SPONSOR","100653478","phase-2-interferon-gamma-plus-camrelizumab-as-neoadjuvant-therapy-for-locally-advanced-esophageal-squamous-cell-carcinoma-100653478",false,"NCT07787273","Interferon Gamma Plus Camrelizumab as Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma","Study of Efficacy and Safety of Interferon Gamma Combined With Camrelizumab for Neoadjuvant Therapy in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma","Inclusion Criteria:\n\n1. Aged \\>= 18 years;\n2. Histologically confirmed esophageal squamous cell carcinoma (ESCC), clinical stage cT1b-3, N+, M0;\n3. Eastern Cooperative Oncology Group (ECOG) performance status 0-1;\n4. Expected overall survival \\> 6 months;\n5. Adequate bone marrow, hepatic, renal, coagulation, and thyroid function.\n\nExclusion Criteria:\n\n1. Active autoimmune disease;\n2. Requirement for systemic immunosuppressive therapy;\n3. Hypersensitivity to any study drug;\n4. Uncontrolled significant organ disease (e.g., cardiac, pulmonary, hepatic, renal) or active infection;\n5. Pregnant or lactating female.","ALL","18 Years",{"count":106,"type":107},84,"ESTIMATED","INTERVENTIONAL",[110],"PHASE2","This study aims to evaluate the efficacy and safety of interferon-gamma combined with camrelizumab plus chemotherapy as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma. Based on previous mechanistic research and preliminary clinical data, this trial intends to generate high-level evidence for this therapeutic strategy, which may improve the treatment landscape for patients with locally advanced esophageal squamous cell carcinoma.",[113,114,56],"Locally Advanced Esophageal Squamous Cell Carcinoma","Neoadjuvant Therapy","2026-08-21",{"date":117,"type":118},"2026-08-26","ACTUAL",{"date":120,"type":118},"2026-03-20",{"date":122,"type":107},"2028-12-31",{"name":5,"class":6},2]